DKY and DRY Peptides Inhibit Angiogenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-angiogenic agents are insufficient in effectively targeting pathological angiogenesis associated with diseases like cancer and chronic inflammation, necessitating the development of new peptides with specific anti-angiogenic activity.
Innovation Solution
Identification and utilization of peptides derived from the U94 gene of Human Herpesvirus 6, specifically the DKY and DRY sequences, which exhibit anti-angiogenic effects by inhibiting blood vessel formation, formulated into pharmaceutical compositions for treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-angiogenic agents are used, then angiogenesis inhibition is achieved, but effectiveness in targeting pathological angiogenesis is insufficient
Solution Approach 1:
The patent extracts the active anti-angiogenic peptide sequences (DKY and DRY) from the U94 gene of Human Herpesvirus 6, isolating the specific functional elements responsible for inhibiting angiogenesis. This extraction approach creates simplified peptide agents that maintain therapeutic effectiveness while reducing complexity compared to full viral proteins or large molecular agents.
Solution Approach 2:
The patent modifies the peptide sequences by substituting amino acids at specific positions (creating variants like ADKY, KAKY, KDAY, KDKA) to optimize anti-angiogenic activity. These parameter changes in amino acid composition allow fine-tuning of the peptides' biological activity and selectivity for pathological angiogenesis.
2Reliability
If new peptides are developed to improve targeting specificity, then effectiveness increases, but development complexity and time increase
Solution Approach 1:
The patent utilizes the naturally occurring U94 gene from Human Herpesvirus 6 as a pre-screened source of anti-angiogenic peptides. The viral gene has already been evolutionarily optimized for biological activity, providing a head start in identifying functional sequences without requiring de novo design and extensive screening of random peptide libraries.
Solution Approach 2:
The patent copies the anti-angiogenic peptide sequences directly from the U94 gene of Human Herpesvirus 6, using the natural viral sequences as templates. This copying approach leverages nature's existing solutions, allowing rapid identification of functional peptides without requiring extensive computational design or random screening processes.
Data Source
AI summary
The present invention relates to a peptide of length equal to or less than 5 amino acids, or a derivative thereof, comprising the sequence DKY, preferably XDKY (SEQ ID No. 7) or DKYX (SEQ ID No. 8), or the sequence DRY, preferably XDRY (SEQ ID No. 9) or DRYX (SEQ ID No. 10), where X is any amino acid, for use as a drug, particularly for use in the treatment of a disorder resulting from pathological angiogenesis, and a pharmaceutical composition comprising it together with at least one pharmaceutically acceptable excipient.